Galderma Introduces Campaign to Address the Hidden Struggles of Atopic Dermatitis

Galderma Launches 'Scratch Resistance' Campaign

In an innovative move, Galderma, the leading company in dermatology, has unveiled its new 'Scratch Resistance' campaign. This initiative aims to raise awareness about the often overlooked emotional and physical burdens experienced by individuals suffering from atopic dermatitis, commonly known as eczema.

Understanding the Issue

Atopic dermatitis affects approximately 26.1 million people in the U.S. every year. The persistent itching associated with this condition not only impacts skin health but can also lead to significant emotional distress. Patients frequently report feelings of anxiety, frustration, and even depression as a result of their skin condition. Understanding this intersection of physical and emotional wellbeing is crucial.

With the 'Scratch Resistance' campaign, Galderma highlights the importance of addressing these multifaceted effects, while at the same time promoting NEMLUVIO® (nemolizumab-ilto), the pioneering neuroimmune-targeted treatment specifically designed for atopic dermatitis. This groundbreaking medication directly targets interleukin-31 (IL-31), a key factor in the itch and inflammation cycle prevalent in patients suffering from this ailment.

The Campaign's Goals

The campaign seeks to empower patients to take charge of their treatment by showcasing the realities of living with atopic dermatitis. It emphasizes that while the itch may be the most recognized symptom, the emotional consequences are equally significant. By promoting the efficacy of NEMLUVIO, Galderma aims to provide relief and restore confidence in those affected.

Debra Hagan, Vice President and General Manager at Galderma, stated, "The impact of itch is often more than skin deep. We hope to bridge the gap between the physical and emotional symptoms of atopic dermatitis. This campaign underscores our commitment to innovation in dermatology and our dedication to improving the quality of life for those living with this condition."

The Disturbing Reality of Itch

According to studies, a staggering 87% of patients express their desire for freedom from their persistent itch. The physical urge to scratch often leads to a cycle of discomfort and sleep disturbances, further complicating the emotional fallout of the condition. With the 'Scratch Resistance' campaign, Galderma seeks to validate the experiences of those who resort to various methods—ranging from household items to specialized tools—to find relief from their itch. The campaign will be visible across multiple platforms, including broadcast television and social media channels such as Facebook and Instagram.

The Promise of NEMLUVIO

NEMLUVIO stands out as the first treatment to halt IL-31 signaling, targeting the core issues that lead to the distressing symptoms of atopic dermatitis. Clinical results indicate that many patients can experience significant relief within just 48 hours of initiating treatment, showcasing the potential for a rapid return to a normal lifestyle.

Following its approval by the U.S. FDA in late 2024, NEMLUVIO is now prescribed to individuals aged 12 and over who continue to struggle with moderate-to-severe atopic dermatitis despite traditional topical therapies. This advancement represents a significant step forward in dermatological innovation, offering hope and much-needed relief for countless individuals.

Looking to the Future

With the launch of the 'Scratch Resistance' campaign, Galderma demonstrates its commitment to understanding and addressing the complexities of atopic dermatitis. Beyond just promoting a product, the campaign seeks to foster awareness and conversation about the deeper implications of skin conditions. Their goal is to uplift patients, ensuring they do not suffer in silence, and to encourage them to explore available treatment options that may lead to improved quality of life.

For more information about this campaign and NEMLUVIO, visit NEMLUVIO's official website.

Conclusion

Galderma's 'Scratch Resistance' campaign is a vital initiative aimed at shedding light on the struggles associated with atopic dermatitis. By focusing on not just the physical but also the emotional aspects of the condition, Galderma hopes to empower patients and lead the way in innovative treatment solutions.